Previous 10 | Next 10 |
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q1 2020 Earnings Call May 11, 2020 , 5:00 p.m. ET Operator Continue reading
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q1 GAAP EPS of -$0.35 misses by $0.05 . More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental Glomerulosclerosis (FSGS) expected Q2 -- -- Completed enrollment of the AURORA clinical trial ...
MOUNTAIN VIEW, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2020 financial results will be released after market close on Monday, May 11, 2020. ChemoCentryx executive management will host a confe...
Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...
The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...
The government's $2 trillion emergency relief package caused shares to skyrocket this week; however, the helicopter-Ben style package may inadequately address mid-term economic instability. If so, then this week's rapid run-up could be a short-term sugar high that wears off in April once disma...
Last week, I wrote "it's time to take a step back, breathe deep, and objectively identify money-making opportunities," and I reminded investors that "if you were in cash during the top 10 best days in the stock market over the past 20 years, then your overall return is half what it would've ...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...